HKU Scholars Hub: Browsing DSpace

Browsing by Author Thongsawat, S

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 16 of 16

	Title	Author(s)	Issue Date	Views
	Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B Proceeding/Conference:Journal of Hepatology	Naoumov, N Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Heathcote, EJ Rasenack, J Bzowej, N Chao, G Brown, N	2006	62
	Evaluation of Estimated Glomerular Filtration Rate During Continuous 4-Year Treatment with Telbivudine in Patients with Bridging Fibrosis/Cirrhosis Proceeding/Conference:Journal of Hepatology	Gane, EJ Lai, CL Xie, Q Liaw, YF Thongsawat, S Chan, HLY Wang, Y Hwang, SG Safadi, R Jung, M Uddin, A Janssens, N Trylesinski, A	2014	56
	Maximal Early Hbv Suppression In Nucleoside-treated Hepatitis B Patients Is Associated With Optimal Virologic And Clinical Efficacy At One Year Journal:Journal of Clinical Virology	Lim, SG Lai, CL Thongsawat, S Wang, Y Chen, Y Rasenack, J Naoumov, N Chao, G Brown, N	2006	105
	Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N the GLOBE Study Group	2005	178
	Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients Proceeding/Conference:Journal of Hepatology	Zeuzem, S Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006	147
	Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B Journal:New England Journal of Medicine	Lau, GK Piratvisuth, T Luo, KX Marcellin, P Thongsawat, S Cooksley, G Gane, E Fried, MW Chow, WC Paik, SW Chang, WY Berg, T Flisiak, R McCloud, P Pluck, N	2005	151
	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research	Lim, HY Merle, P Weiss, KH Yau, TCC Ross, P Mazzaferro, V Blanc, JF Ma, YT Yen, CJ Kocsis, J Choo, SP Sukeepaisarnjaroen, W Gérolami, R Dufour, JF Gane, EJ Ryoo, BY Peck-Radosavljevic, M Dao, T Yeo, W Lamlertthon, W Thongsawat, S Teufel, M Roth, K Reis, D Childs, BH Krissel, H Llovet, JM	2018	50
	Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year Proceeding/Conference:Journal of Hepatology	Gane, E Lai, CL Liaw, YF Thongsawat, S Wang, YM Cheng, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006
	Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year Proceeding/Conference:Gastroenterology	Bzowej, N Lai, CL Gane, E Liaw, Y Thongsawat, S Wang, Y Chen, Y Heathcote, J Rasenack, J Naoumov, N Chao, G Fielman, B Brown, N	2006	124
	Responses to peginterferon alfa-2a (40KD) (PEGASYS) treatment are durable in Asian Patients with HBeAg-Negative CHB: 12 month Follow-Up Data from a large Randomised Study Proceeding/Conference:Journal of Gastroenterology and Hepatology	Marcellin, P Lau, GKK Piratvisuth, T Jin, R Lu, ZM Lai, MY Thongsawat, S Ramakrishnan, B Popescu, M	2006
	Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N and the GLOBE Study Group, .	2005
	Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study Proceeding/Conference:Journal of Hepatology	Thongsawat, S Lai, CL Gane, E Chao, G Fielman, B Brown, N GLOBE Investigator Group, .	2006	117
	Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients Proceeding/Conference:Hepatology	DiBisceglie A, A Lai, CL Gane, E Chen, YC Thongsawat, S Wang, YM Chen, YG Heathcote, EJ Zeuzem, S Rasenack, J Bzowej, N Han, SH Naoumov, N Hwang, SG Lim, SG Chao, GC Fielman, BA Brown, NA Study Group The GLOBE,	2006	100
	Telbivudine versus lamivudine in patients with chronic hepatitis B Journal:New England Journal of Medicine	Lai, CL Gane, E Liaw, YF Hsu, CW Thongsawat, S Wang, Y Chen, Y Heathcote, EJ Rasenack, J Bzowej, N Naoumov, NV Di Bisceglie, AM Zeuzem, S Moon, YM Goodman, Z Chao, G Constance, BF Brown, NA	2007	135
	Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response Proceeding/Conference:Hepatology International	Lai, CL Gane, E Hsu, CW Chen, YC Thongsawat, S Wang, Y Chen, Y Naoumov, N Han, SH Hwang, SG Lim, SG Brown, NA	2007	163
	Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine Proceeding/Conference:Hepatology	Lai, CL Gane, E Hsu, CW Thongsawat, S Wang, YM Chen, YG Heathcote, EJ Rasenack, J Bzowej, N Naoumov, N Zeuzem, S Di Bisceglie, A Chao, GC Barbara, A Constance, F Brown, NA Study Group The GLOBE.,	2006	162

Showing results 1 to 16 of 16